Nerac

Information That Drives Innovation

We’re here to help with your research needs
+1 860 872 7000
Customer Access
  • Home
  • What We Do
    • Innovation Insights and Consulting Practice
    • Regulatory
    • Medical Device and Life Sciences
    • Technology Scouting and Innovation
    • Market Research
    • Intellectual Property
    • Commercialization Services for TTOs and Start-Ups
    • Critical Updates
  • Who We Serve
  • How to Engage
  • Why Nerac?
  • Meet our Team
    • Leadership Team
    • Our Analysts
    • Our Partners
  • Nerac Insights and Publications
    • Articles
    • Case Studies
    • Press Room
    • Videos
    • Webcasts
    • White Papers
  • Contact Us
You are here: Home / Nerac Insights / Articles / Exciting Novel, but High-Cost Developments in Cancer Treatment: Immunotherapy continues to advance as a validated approach

Exciting Novel, but High-Cost Developments in Cancer Treatment: Immunotherapy continues to advance as a validated approach

Facebook0
Google+0
LinkedIn0
Twitter0
By Holly Magna, Ph.D., Nerac Analyst,
Originally Published: November 28, 2016

New developments in Immunotherapy continue to advance and show promising results in treatment of a variety of cancers. This article reviews some of the newly marketed therapies and some still in development, as well as their complications, risks and advantages.

Want to read the rest of the article? Fill out the form to download:Graphene: Quest for the Killer App
Get Download Link

Related Posts

  • Nerac Announces December Issue of the Nerac Strategist
    36
    New issue explores innovations in cancer treatments, graphene and drug safety updates. Read the full release here.
    Tags: nerac, read, originally, published, cancer, treatments, immunotherapy
  • A Glimpse into the Vital Core of Tumor Cell Development
    31
    By John Leavitt, Ph.D. Nerac Analyst Originally Published: August 12, 2014 In 1987, my colleagues at Stanford and I published a paper that clearly demonstrated that expression of a charge-altered mutant human beta-actin (glycine to aspartic acid substitution at amino acid 245; G245D) caused non-tumorigenic, immortalized human fibroblasts to form aggressive tumors in nude mice (Leavitt…
    Tags: published, read, form, ph.d, analyst, originally, nerac, article, development, cancer
  • The Holy Grail of Cancer Research – A Protein That Enables Aggressive Tumor Growth and Metastasis
    30
    By John Leavitt, Ph.D. Nerac Analyst Originally Published July 21, 2014 Such a protein appears to be described in a paper published in the journal Molecular Cancer Therapeutics in February 2014 by Heinz-Josef Lenz at the Keck School of Medicine of the University of Southern California in collaboration with colleagues at the University of Graz in…
    Tags: cancer, read, ph.d, nerac, published, analyst, article, variety
  • Case Studies
  • White Papers
  • Webcasts
  • Articles
    • Nerac Strategist
    • Energy
    • Food & Nutrition
    • Intellectual Property
    • Regulatory
    • Technology & Innovation
    • Medical Device & Healthcare
    • Pharmaceutical
    • Engineering
    • Market Research
    • Critical Alerts
    • Chemistry/Advanced Materials
  • Press Room

Click here to learn more about….

3d printing advanced materials aerospace Ask Kevin Videos biotech CFDA clinical literature evaluations commercialization strategies competitive intelligence Disruptive Technologies emerging markets energy EU MDR FDA food helga weires Industry 4.0 innovation Inspiring Next intellectual property intellectual property strategies IP market analysis market research medical device medical devices nerac Nerac client questions Nerac Strategist notified body audit open innovation Order 650 patenting strategies patent landscape pharmaceutical Post-Market Surveillance R&D regulatory regulatory compliance Robert Beinstein Rosemarie Szostak specialty chemicals Sustainable Development Goals technology scouting XcellR8
  • Facebook
  • Google+
  • LinkedIn
  • RSS
  • Twitter
  • YouTube
  • Career Opportunities
  • Privacy Policy

Copyright © 2022 Nerac · One Technology Drive · Tolland, CT 06084 · 1.860.872.7000

Sign Up for the Nerac Strategist

Like what you see? Sign up here to receive the Nerac Strategist newsletter, a compilation of analyst insights on rapidly developing industry issues, compliance challenges and commercial opportunities!
  • This field is for validation purposes and should be left unchanged.